m+Medelevator.RU
← Поиск публикаций
Journal of ethnopharmacology · 2025

Efficacy of the herbal product of Cuscuta campestris Yunck. and Polypodium vulgare L. in patients with obsessive-compulsive disorder: A triple-blind clinical trial.

СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Bakhshinejad Behnaz, Sabahi Abdolreza, Dehesh Tania, Sarhadynejad Zarrin, Mehrabani Mehrnaz, Khazaneha Mahdiyeh, Mehrbani Mehrzad, Mehrabani Mitra

Аннотация

ETHNOPHARMACOLOGICAL RELEVANCE: Cuscuta campestris Yunck. and Polypodium vulgare L. are medicinal plants widely used in traditional Persian medicine to treat various mental health conditions, such as Obsessive-compulsive disorder (OCD).

AIM OF THE STUDY: OCD is among the top ten disorders that cause disability and decrease quality of life. Considering the lack of a definitive treatment method and the side effects of the existing drugs, the application of complementary medicine in treating this disorder seems reasonable. The current study aimed to investigate the therapeutic impact of a dodder and polypody herbal product (DPHP) in OCD patients.

MATERIALS AND METHODS: In this triple-blind clinical trial, 84 individuals with OCD were assigned to two groups of DPHP and placebo receivers at random. While taking fluvoxamine tablets (100 mg twice daily), the first group was prescribed DPHP tablets, and the second group was prescribed placebo tablets twice daily. The intensity of manifestations and the participant's quality of life were evaluated at the beginning of the trial and after four and eight weeks of intervention using the Yale-Brown and WHOQOL-BREF questionnaires, respectively.

RESULTS: The severity of OCD symptoms in both groups decreased significantly after four and eight weeks (P-value <0.001). The DPHP group's reduction rate was significantly higher than the placebo group (P-value = 0.043). The quality of life improved significantly in both groups (P-value <0.001). However, the increase in the quality of life in the DPHP group was significantly higher compared to the placebo group (P-value = 0.042).

CONCLUSIONS: DPHP, taken alongside fluvoxamine, can effectively alleviate the symptoms of OCD and increase the quality of life. Therefore, it could be regarded as a complementary therapeutic alternative to OCD.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты